RenaGel Geltex Pharmaceuticals Inc

IDrugs

Volumn 2, Issue 2, 1999, Pages 146-152

  Von Appen, Kai ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATE BINDING AGENT; POLYMER; RENASTAT; SEVELAMER; UNCLASSIFIED DRUG;

CHRONIC KIDNEY FAILURE; DRUG ABSORPTION; DRUG MARKETING; DRUG METABOLISM; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HYPERPHOSPHATEMIA; SHORT SURVEY; UREMIA;

EID: 0032995072     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (71)

1. BTG/Vanguard join on kidney drug. SCRIP 1994 1974 25
2. GelTex Pharmaceuticals Inc (company brochure) GelTex Pharmaceuticals Inc COMPANY BROCHURE 1995 July 21
3. Geitex $26 mil IPO will fund Cholestagel, Renagel polymer-based pharmaceutical development, GeneMedicine raises over $18 mil in secondary public offering FDC REPORTS PINK SHEET 1995 57 49 12-13
4. RenaGel CLIN TRIALS MONITOR 1995 4 12 P11
5. GelTex Pharmaceuticals reports positive phase lib clinical results for RenaGel phosphate binder GelTex Pharmaceuticals Inc PRESS RELEASE 1996 May 9 Dose-finding phase II study.
6. GelTex Pharmaceutical begins Phase III clinical trials of RenaGel phosphate binder GelTex Pharmaceuticals Inc PRESS RELEASE 1996 June 17
7. GelTex Renastat trials soon? SCRIP 1994 1971 31
8. Clinical trial update BIOWORLD FINANCIAL WATCH 19964318
9. Drug development pipeline June 1996 DRUG DEV P/PEL//VE199612
10. 219433 GelTex Pharmaceuticals Inc ANNUAL REPORT 1995 December
11. GelTex's partner, Chugai Pharmaceutical, initiates Phase I clinical trials in Japan of RenaGel phosphate binder GelTex Pharmaceuticals Inc PRESS RELEASE 1996 December 2 Clinical studies in Japan and the US.
12. Chugai developing RenaGel in Japan: SCRIP 1996 2189 19
13. GelTex Pharmaceuticals ANALYST REPORT 1996 May 15
14. Clinical trials update SCRIP 1997 2198 22
15. GelTex Pharmaceuticals reports positive results from second phase III clinical trial for RenaGel phosphate binder. GelTex Pharmaceuticals Inc PRESS RELEASE'1997 March 10 Phase /// crossover comparison; NDA submitted to the US PDA by GelTex to market RenaGel; marketing policy for the US, Europe and Canada.
16. Xoma presents data from meningococcemia trial at London symposium PRESS RELEASE 1996 March 14
17. GelTex reports positive RenaGel data BIOWORLD WEEK 1997 5 11 3
18. Medlmmune's RespiGam DRUG DEV PIPELINE 1997 2 2 1-4
19. GelTex announces positive preliminary phase He results for RenaGel phosphate binder company also receives second patent on cholesterol reducing polymers GelTex Pharmaceutical Inc PRESS RELEASE 1997 April 8 Phase II study in predialysis patients.
20. GelTex Pharmaceuticals reports first quarter 1997 results GelTex Pharmaceutical Inc PRESS RELEASE 1997 April 28
21. Clinical trials update SCRIP 1997 2227 27
22. Genzyme paying GelTex S27.5M for Renagel BIOWORLD WEEK 1997 5253
23. New drugs in the R & D pipeline: Chugai Pharmaceutical PHARMAJPN19971556 19
24. Chugai Pharmaceutical Co Ltd ANNUAL REPORT 1997 March 31
25. GelTex Pharmaceuticals reports second quarter 1997 results GelTex Pharmaceuticals Inc PRESS RELEASE 1997 July 28
26. Genzyme General posts record EPS of $.31 in third quarter Genzyme Corp PRESS RELEASE 1997 October 23
27. GelTex Pharmaceuticals reports third quarter 1997 results GelTex Pharmaceuticals Inc PRESS RELEASE 1997 October 27
28. GelTex Pharmaceuticals submits NDA for RenaGel nonabsorbed phosphate binder GelTex Pharmaceuticals Inc PRESS RELEASE 1997 November 3 NDA submitted to the US PDA by GelTex to market RenaGel; marketing policy for the US, Europe and Canada.
29. GelTex Seeks FDA approval of RenaGel BIOWORLD WEEK 1997 5 45 2
30. GelTex files RenaGel NDA. SCRIP 1997 2283 26
31. GelTex Pharmaceuticals' NDA for RenaGel nonabsorbed phosphate binder accepted as 'filable1 by PDA/Company also announces receipt of 'Part B' status for European Marketing Approval filings for RenaGel GelTex Pharmaceuticals Inc PRESS RELEASE 1998 January 5
32. New US co-marketer & indication for Penederm's Mentax. SCRIP 1998 2296/97 8
33. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Burke SK, Slatopolsky EA, Goldberg DI NEPHROL DIAL TRANSPLANT1997 12 8 1640-1644
34. Phase I data; in vivo study in healthy volunteers, characterizing phosphate kinetics following RenaGel administration.
35. GelTex progress with RenaGel/CholestaGel SCRIP 1998 2299 16
36. GelTex Pharmaceuticals Reports 1997 fourth quarter and year end results GelTex Pharmaceuticals Inc PRESS RELEASE 1998 February 11
37. Chugai, Kirin to codevelop antihyperphosphatemia PHARMA JPN1998 1586 4
38. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion i.i rats. Rosenbaum DP, Holmes Parley SR, Mandeville WH, Pitruzzello M, Goldberg DI NEPHROL DIAL TRANSPLANT'1997 12 5961-964
39. In vitro phosphate binding study with RenaGel, including description of high binding capacity. Also includes in vivo (animal experiments) evaluation of phosphate kinetics following administration of RenaGel.
40. Efficacy of a nonabsocbable phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Reiner D, Kem M, Burke S, Wilkes B J AM SOC NEPHROL 1997 9 Prog Abs Issue 566A
41. Poly(allylamine) hydrochloride (RenaGel) (RG) with and without supplemental calcium (C) for hyperphosphatemia (HP) in ESRD. Chertow GM, Burke SK, Goldberg D, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolosky E J AM SOC NEPHROL 1997 9 Prog Abs Issue 549A
42. Phase lib study of phosphate binding capacity of RenaGel with calcium supplementation in hemodialysis patients.
43. An open label, cross-over study of the new phosphate binder RenaGel in the management of hyperphosphatemia in ESRD patients. Bleyer AJ, Garrett B, Kant KS. Lynch D, Rahman N, Schoenfeld P, Teitelbaum l, Zeig S, Slatopolsky E J AM SOC NEPHROL 1997 9 Prog Abs Issue 548A
44. Phase III study; dose titration and comparison with PhosLo (calcium acetate).
45. In vitro and in vivo efficacy of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder. Rosenbaum DP, Homes Parley SR, Mandeville WH, Pitruzzello M, Goldberg DI FASEB J 1997 113A275
46. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E AM J KIDNEY DIS I9B7 23 1 66-71
47. Phase II study of the phosphate binding capacity of RenaGel in hemodialysis patients.
48. Effect of RenaGel, a novel phosphate binder, on serum phosphorus and parathyroid hormone levels in end stage renal disease (ESRD) patients. Slatopolsky E, Garrett B, Gray J, Marbury T, Weinberg M, Wombolt D, Burke S, Goldberg D, Bonventre J JAM SOC AEPHflOi.1996791818
49. Multi-center study of the efficiency of phosphate binding of RenaGel.
50. House bill to establish CQI program for dialysis facilities and to require outcomes disclosure in the works. DIALYSIS TRANSPLANT 1996 25 9 548-554+556+560+562-563+567
51. RenaGel-TM, a calcium and aluminum free phosphate binder, lowers serum phosphorus in hemodialysis patients. Burkel SK, Goldberg DI, Bonventre JV, Slatopolsky EA NEPHROL DIAL TRANSPLANT 199611 6 A41
52. Evaluation of phosphate lowering capacity of RenaGel; description of cholesterol lowering effects.
53. RenaGel, a calcium and aluminum free phosphate binder, inhibits phosphate absorption in normal volunteers. Burkel SK, Goldberg Dl, Bonventre JV, Slatopolsky EA NEPHROL DIAL TRANSPLANT 1996 11 6 A40
54. Pharmaceutical & Biotechnology Bulletin Merrill Lynch ANALYST REPORT 1998 16 March
55. Geltex investment takes international biotechnology trust close to full investment, 'C' share investment triggered International Biotechnology Trust PRESS RELEASE 1998 April 9
56. Genzyme General Reports 15 percent growth in earnings per share Genzyme Corp PRESS RELEASE 1998 April 23
57. GelTex Pharmaceuticals reports first quarter 1998 results GelTex Pharmaceuticals Inc PRESS RELEASE 1998 April 27
58. GelTex Pharmaceuticals and Genzyme report positive preliminary results of extended use clinical trial of RenaGel non-absorbed phosphate binder; RenaGel program updated at Cruttenden Roth financial conference. GelTex Pharmaceuticals Inc PRESS RELEASE 1998 June 29 Multicenter phase III study in 192 hemodialysis patients, detailing phosphate lowering effect, stable serum calcium, decrease in serum parathormone levels.
59. Stages of biotech growth evolving through experience. 1997 Annual Meeting of the Massachusetts Biotechnology Council (MBC). Morville M, Ferguson AR, Petkevich JM, Bishop RC, Gonzalez JE, Skaletsky M, Wilcox III HW, Sorvillo JM, Purcell DJ, Crane AL, Wirth P J B1OLAWBUSINESS 19971 1 18-51
60. GelTex, Genzyme General submit European Marketing Application for RenaGel non-absorbed phosphate binder GelTex Pharmaceuticals Inc PRESS RELEASE 1998 July 7
61. GelTex Pharmaceuticals reports second quarter 1998 results GelTex Pharmaceuticals Inc PRESS RELEASE 1998 July 27
62. Chugai Pharmaceutical Co Ltd ANNUAL REPORT 1998 August
63. Pharmaceutical and biotechnology bulletin Merrill Lynch ANALYST REPORT 1998 August
64. New drugs in the R&D pipeline PHARMA JPN1998 Extra issue 1611 24 August 1
65. Genzyme General ANNUAL REPORT1997
66. Pharmaceutical & Biotechnology Bulletin Merrill Lynch ANALYST REPORT 1998 1 October 1998
67. Pharmaceutical and Biotechnology Bulletin Merrill Lynch ANALYST REPORT 1998 15 June
68. Genzyme General reports record third quarter earnings Genzyme General PRESS RELEASE 1998 October 22
69. GelTex Pharmaceuticals reports third quarter 1998 results GelTex Pharmaceuticals Inc PRESS RELEASE 1998 October 26
70. Genzyme's earnings reflect continued therapeutics growth BIOWORLD WEEK 1998 6 43 4
71. GelTex, Genzyme announce PDA marketing approval for Renag! capsule. GelTex Pharmaceuticals Inc PRESS